News: Jun 02, 2009
It may be possible in the future to use a specimen from the tumour to determine which patients with breast cancer have a good chance of overcoming the disease, and which patients should be given more intensive treatments. Fifty-one genes may together provide information about the prognosis for an individual patient. These are the conclusions of a thesis presented at the Sahlgrenska Academy.
The research group has analysed specimens from a number of breast tumours, both from patients that died from the disease and from patients surviving at least 10 years from diagnosis. The levels of expression of
51 genes differed between the two groups. It should be possible to use the differences in order to classify the patients into one of two
groups: a favourable prognosis group and a poor prognosis group.
"Many breast cancer patients are currently overtreated, while some are undertreated. If it was possible to identify patients with poor prognosis, it would be possible to use greater treatment resources on these patients. At the same time, patients with a favourable prognosis could avoid unnecessary treatment", says research student Elin Karlsson.
Comparing the amounts of the gene products of these 51 genes with data from a previous study has allowed the research team to show that the genes have the ability to predict survival also for the new material.
The research group has also studied the protein BTG2, and shown that it is involved at several levels in the tumours that were examined. The protein was present more often in specimens from patients who had survived at least 5 years after diagnosis than in patients who had died within 5 years from diagnosis. It has been previously determined that this protein is a tumour suppressor, but the study at the Sahlgrenska Academy is the first to indicate it as a prognostic marker.
"We consider it to be a promising marker: it will maybe be possible to use it to determine which patients with breast cancer require particularly close surveillance. More research, however, will be required in order to confirm our results before analysis of the protein can be used in the clinic", says Elin Karlsson.
Breast cancer is the most common form of cancer in women, and only lung cancer causes more deaths. Approximately 7,000 people are affected by breast cancer in Sweden each year, a few of whom are men. The most common treatment is removal of all or parts of the breast, with supplementary radiation therapy, hormonal therapy or chemotherapy.
Ever-increasing numbers of patients in Sweden are beating the disease, and the current survival rate is nearly 75%.
For more information, contact:
Elin Karlsson, molecular biologist. Telephone: +46 31 342 7855, Mobile:
+46 70 983 7370, E-mail
Associate professor Khalil Helou. Telephone: +46 31 342 8443, E-mail
A thesis presented for the degree of Doctor of Philosophy (Medicine) at the Sahlgrenska Academy, Institute of Clinical Sciences, Department of Oncology.
Title of the thesis: Novel biomarkers predicting long-term survival in breast cancer
The thesis will be defended on Friday 5 June at 1 p.m. in the Ivan Ivarsson lecture theatre, Academicum, Medicinaregatan 3, Gothenburg, Sweden.
The thesis can be downloaded from: http://hdl.handle.net/2077/20043.